Gufic Biosciences Files SEBI Compliance Certificate for Q1 FY27
Gufic Biosciences Limited submitted a compliance certificate for the quarter ended June 30, 2026. The certificate, received from RTA MUFG Intime India, confirms the proper processing and cancellation of dematerialized securities as per SEBI regulations.
This is a standard regulatory filing that is part of the normal course of business for a listed company. It does not introduce any new material information that would significantly affect the company's operations or market perception.
The announcement is a routine compliance filing and does not contain any new financial information or strategic developments that would impact the company's stock price.
Gufic Biosciences Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended June 30, 2026. The company received this confirmation from its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited (formerly Link Intime India Private Limited).
The RTA confirmed that securities received from depository participants for dematerialization during the quarter were processed and confirmed with the depositories. They also stated that the security certificates received for dematerialization were subsequently cancelled and replaced with depository names in the register of members within the stipulated timelines.
The certificate ensures compliance with SEBI regulations regarding the handling of securities and their dematerialization process, providing assurance to investors and regulatory bodies about the integrity of share records.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.